Rituximab

Rituximab a,ɛyɛ adwumakuo Rituxan ne nnwumakuo ahodoɔ binom na wɔtɔn no,yɛ aduro a wɔde hwɛ nyarewa ahodoɔ bi ne kokoram yareɛ ahodoɔ binom.

 Yareɛ A Wɔde Sa 
Rituximab yɛ nnuro a wɔde ko tia CD20, a ɛwɔ B cells honam ani.Ɛyɛ adwuma sɛdeɛ ɛpepa  B cells wedeɛ no ani no a ɛma plasma  cells hematopoietic stem cells no a ɛnkyerɛ CD20 no.

 Nsunsuansoɔ 
Ɛho nsunsuansoɔ a ano yɛ den no tumi de owuo ba.

 Abakɔsɛm 
IDEC nnuro adwumakuo a ɛhyɛ IDEC C2B8 na wɔyɛɛ Rituximab. US man a wɔyɛɛ aduro no de too dwa 1998 na ɛwuu wɔ 2015

 Asetena Ne Amammerɛ 

 Ekɔnɔmiks 
Wɔ 2014, Genentech sane hyehyɛɛ Rituxan sɛ aduro soronko, adurokuo a na ɛwɔ US,wɔn   a wɔtɔn nnuro nko ara.Ɛfiri sɛ wɔn a wɔfa no atufoɔboɔ no rentua sika biara,na mmom asupiti na wɔbɛtua.

 Nhwehwɛmu 

 Myalgic encephalomyelitis/chronic fatigue syndrome 
Wɔ 2009,ayarefoɔ a wɔgye methotrexate B-cell no hunuu encephalomyelitis anaa sɛ koankorɔ(ME/CFS)ho mpopeɛ.

 Beaeɛ A Menyaa Mmoa Firiiɛ